Moderate to Severe Plaque Psoriasis
Conditions
Brief summary
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
Interventions
SHR-1139 injection.
DRUGSHR-1139 Injection Placebo
SHR-1139 injection placebo.
Sponsors
Guangdong Hengrui Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, age ≥ 18 years old at the time of signing the informed consent form (ICF). 2. Subjects voluntarily sign informed consent form (ICF) prior to the commencement of any procedures related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical study protocol. 3. A fertile female subject or a male subject whose partner is a fertile woman who has not had a child, has a sperm/egg donation plan for 72 weeks from the date of signing the informed consent form to the last dose, and is voluntarily using highly effective contraception (including the partner). 4. Female subjects must have negative pregnancy test results during the screening period and before randomized administration, and must be non-lactating.
Exclusion criteria
1. There are other skin problems that researchers believe can interfere with the evaluation of psoriasis. 2. A history of moderate to severe congestive heart failure, cardiovascular and cerebrovascular events or severe bleeding events occurred in the 3 months before screening, and the investigator considered this subject to be unfit for clinical study. 3. Had an opportunistic infection within 6 months prior to screening. 4. Allergic to the ingredients or excipients of the study drug. 5. The investigator determined that there were conditions that affected the safety and efficacy evaluation of the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects with at least 90% improvement (PASI 90) in their PASI (Psoriasis Area and Severity Index) score from the baseline. | At week 16. |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects with at least 75% improvement (PASI 75) in their PASI (Psoriasis Area and Severity Index) score from the baseline. | At week 16. |
| Proportion of subjects with at least 100% improvement (PASI 100) in their PASI (Psoriasis Area and Severity Index) score from the baseline. | At week 16. |
| Adverse events (AEs) | Up to week 64. |
| Serum concentration of SHR-1139. | Up to week 64. |
Countries
China
Outcome results
None listed